ClinicalTrials.gg
TerminatedNCT00383331Updated Jun 3, 2009Results posted

Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer

A Phase 2 interventional study of Pemetrexed and Gemcitabine in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-03.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial was stopped early due to low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
173rd of 223
19 · median 64
Started
2007
with 11 others
Phase 2
128 of 227
12 open now
Registered
41st of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 173rd largest by enrollment of the 223 interventional ones that give a count, is one of 12 that started in 2007, is one of 128 in phase 2, and was the 41st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is designed to evaluate Pemetrexed and Gemcitabine Day 1 followed by Gemcitabine Day 8 every 21 days (Arm A) and Pemetrexed and Gemcitabine Day 1 every 14 days (Arm B) in patients with NSCLC. Each agent and sequence has well demonstrated antitumor activity respectively in patients with locally advanced or metastatic NSCLC. Therefore, it is reasonable to investigate the most optimal schedule for this combination, and which combination is associated with the most anti-tumor activity in the phase II arena.

03

Conditions studied

  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • histologic or cytologic diagnosis of NSCLC Stage IIIB or IV
  • no prior systemic chemotherapy for advanced Non-Small Cell Lung Cancer
  • Prior radiotherapy must be completed at least 4 weeks before study enrollment.

Exclusion criteria

Exclusion Criteria:

  • estimated of 12 weeks
  • a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease
  • documented unless the patient has completed successful local therapy for central nervous system and has been off of for at least 2 weeks before enrollment
  • significant weight loss (that is, > 10%) over the previous 6 weeks before study entry.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    A

    Drug: Pemetrexed · Drug: Gemcitabine

  • Experimental
    B

    Drug: Pemetrexed · Drug: Gemcitabine

Interventions

  • A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles

    Also known as: LY231514, Alimta

  • A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles

    Also known as: LY188011, Gemzar

06

What researchers measure

Primary outcomes

  1. Best Overall Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

    Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up

Secondary outcomes

  1. Progression Free Survival

    baseline to measured progressive disease

    Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up

  2. Time to Progressive Disease

    Time to progressive disease not analyzed because trial was stopped early due to low enrollment.

    Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up

  3. Duration of Response

    Duration of response was not analyzed because the trial was stopped early due to low enrollment.

    Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up

  4. Time to Treatment Failure

    Time to treatment failure was not analyzed because the trial was stopped early due to low enrollment.

    Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up

  5. Overall Survival

    Survival time is defined as the time from date of randomization to death due to any cause.

    Time frame: baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up

07

Results

Posted May 14, 2009
Limitations and caveats
Trial was stopped early due to low enrollment. Some secondary outcomes were not analyzed due to the low numbers.

Participant flow

Participant flow — Overall Study
Milestone21-Day Cycle14-Day Cycle
Started109
Completed108
Not completed01
Withdrew: Protocol violation01

Outcome measures

PrimaryBest Overall Tumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

Time frame:
baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Reported as:
Number · participants
Best Overall Tumor Response
participants21-Day Cycle14-Day Cycle
Complete Response00
Partial Response20
Statistical analysis
  • 21-Day Cycle vs 14-Day Cycle · Fisher Exact · p = 0.48
SecondaryProgression Free Survival

baseline to measured progressive disease

Time frame:
baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Reported as:
Median · months
Progression Free Survival
months21-Day Cycle14-Day Cycle
Progression Free Survival1.66 (0.69 to 4.30)5.04 (1.74 to 5.95)
SecondaryTime to Progressive Disease

Time to progressive disease not analyzed because trial was stopped early due to low enrollment.

Time frame:
baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryDuration of Response

Duration of response was not analyzed because the trial was stopped early due to low enrollment.

Time frame:
baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryTime to Treatment Failure

Time to treatment failure was not analyzed because the trial was stopped early due to low enrollment.

Time frame:
baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryOverall Survival

Survival time is defined as the time from date of randomization to death due to any cause.

Time frame:
baseline and every 14 or 21 day cycle (6-9 cycles), every 6 weeks post-therapy follow-up
Reported as:
Median · months
Overall Survival
months21-Day Cycle14-Day Cycle
Overall Survival5.1 (2.4 to 14.2)8.1 (5.5 to 10.1)
Statistical analysis
  • 21-Day Cycle vs 14-Day Cycle · Log Rank · p = 0.56

Adverse events

Non-serious events are listed at a 15% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
21-Day Cycle———
14-Day Cycle———
Most frequent serious events
Most frequent serious events
Event21-Day Cycle14-Day Cycle
FatigueGeneral disorders0/102/9
NeutropeniaBlood and lymphatic system disorders2/102/9
Disease Progression - DeathNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/100/9
ThrombocytopeniaBlood and lymphatic system disorders1/100/9
Ischemia-CerebralNervous system disorders1/100/9
LeukopeniaBlood and lymphatic system disorders1/100/9
Pain - ExtremityGeneral disorders1/100/9
AnemiaBlood and lymphatic system disorders1/100/9
Most frequent other events
Showing 10 of 14
Most frequent other events
Event21-Day Cycle14-Day Cycle
AnemiaBlood and lymphatic system disorders8/108/9
LeukopeniaBlood and lymphatic system disorders8/108/9
NauseaGastrointestinal disorders5/107/9
ThrombocytopeniaBlood and lymphatic system disorders7/102/9
NeutropeniaBlood and lymphatic system disorders6/106/9
FatigueGeneral disorders6/104/9
Pneumonia NOSRespiratory, thoracic and mediastinal disorders0/104/9
Diarrhea-No ColostomGastrointestinal disorders4/102/9
AnorexiaPsychiatric disorders2/103/9
ConstipationGastrointestinal disorders3/101/9

Baseline characteristics

Age Continuous
Age Continuous(years)21-Day Cycle14-Day CycleTotal
Median70.5 (60.0 to 81.0)63.0 (48.0 to 74.0)66.0 (48.0 to 81.0)
Sex: Female, Male
Sex: Female, Male(Participants)21-Day Cycle14-Day CycleTotal
Female538
Male5611
Region of Enrollment
Region of Enrollment(participants)21-Day Cycle14-Day CycleTotal
United States10919
Eastern Cooperative Oncology Group Performance Score
Eastern Cooperative Oncology Group Performance Score(participants)21-Day Cycle14-Day CycleTotal
0 - Fully Active448
1 - Ambulatory, Restricted Strenuous Activity6511
2 - Amublatory, No Work Activities000
3 - Partially Confined to Bed, Limited Self Care000
4 - Completely Disabled000
Previous Radiation Therapy
Previous Radiation Therapy(participants)21-Day Cycle14-Day CycleTotal
Yes314
No7815
Stage of Lung Cancer
Stage of Lung Cancer(participants)21-Day Cycle14-Day CycleTotal
IIIB with pleural effusion224
IV8715
Tumor Cell Type
Tumor Cell Type(participants)21-Day Cycle14-Day CycleTotal
Squamous123
Adenocarcinoma538
Non-Small Cell Lung, Not Otherwise Specified (NOS)426
Other022
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, Minnesota 55905, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2006
First posted
Oct 3, 2006
Start
Feb 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
May 14, 2009
Last update
Jun 3, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00383331
First posted
Oct 3, 2006
Start date
Feb 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
May 14, 2009
Last update
Jun 3, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Gemcitabine

Start the discussion